Brett Zundel
Medical · Terreton, IDNPI 1730222365
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,592 of the $70,529 with a category attached, or 81.7%. Novo Nordisk accounts for 92.8% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $29,438 and has fallen 78.8% since, to $6,252 in 2025. Among medical clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 368 payments — averaging $191.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$65K
- Medtronic$2K
- Novartis$381
- Lilly USA, LLC$362
- Abbott$256
- Insulet Corporation$206
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$57,59282%
- Travel & lodging$7,72911%
- Food & beverage$5,1897%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 134 | $65,445 |
| Medtronic | 18 | $1,770 |
| Novartis | 41 | $381 |
| Lilly USA, LLC | 21 | $362 |
| Abbott | 23 | $256 |
| Insulet Corporation | 10 | $206 |
| Esperion Therapeutics, Inc. | 6 | $167 |
| Boehringer Ingelheim | 7 | $161 |
| Amgen(2 entities) | 5 | $155 |
| Bayer | 9 | $141 |
| Radius Health, Inc. | 7 | $133 |
| Amarin Pharma, Inc. | 10 | $118 |
| Xeris Pharmaceuticals, Inc. | 7 | $113 |
| Sanofi-aventis U.S. LLC | 8 | $109 |
| Corcept Therapeutics | 7 | $102 |
| AbbVie | 5 | $98 |
| Ascendis Pharma Endocrinology Inc | 6 | $92 |
| Recordati_rare_diseases_inc. | 4 | $73 |
| Ultragenyx Pharmaceutical Inc. | 5 | $70 |
| AstraZeneca | 5 | $62 |
| Johnson & Johnson | 4 | $62 |
| Amryt Pharma Holdings Ltd | 3 | $56 |
| IBSA Pharma Inc. | 4 | $47 |
| Dexcom, Inc. | 1 | $38 |
| Kyowa Kirin, Inc. | 2 | $34 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Pfizer | 2 | $33 |
| Nestle Healthcare Nutrition Inc. | 2 | $33 |
| Rhythm Pharmaceuticals, Inc. | 2 | $29 |
| Chiasma, Inc. | 1 | $26 |
| Merck | 2 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Eton Pharmaceuticals, Inc. | 1 | $19 |
| Nevro Corp. | 1 | $16 |
| EUSA Pharma (US) LLC | 1 | $15 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Halozyme Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$70,529 in reported general payments places this provider in the 95th percentile of 265 medical providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 311 | $315,872 |
| MounjaroTirzepatide | 180 | $193,901 |
| FarxigaDapagliflozin Propanediol | 188 | $144,007 |
| TrulicityDulaglutide | 114 | $123,883 |
| JardianceEmpagliflozin | 122 | $108,192 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $78,212 |
| Tresiba Flextouch U-100Insulin Degludec | 71 | $45,154 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $32,036 |
| EliquisApixaban | 35 | $29,946 |
| Repatha SureclickEvolocumab | 19 | $29,346 |
| LinzessLinaclotide | 44 | $27,715 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 155 | $20,827 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $20,128 |
| RybelsusSemaglutide | 13 | $17,308 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $11,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $65,445 | $333,180324 claims |
| Lilly USA, LLCMounjaro, Trulicity | $362 | $317,784294 claims |
| AstraZenecaFarxiga | $62 | $144,007188 claims |
| Boehringer IngelheimJardiance, Synjardy | $161 | $115,216134 claims |
| PfizerEliquis | $33 | $29,94635 claims |
| AbbVieLinzess | $98 | $27,71544 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 265 medical providers in Idaho.
Other medical in Terreton
- Jessica BishopBoise$60K
- Kyle GeorgeMeridian$19K
- Jed BartschiIdaho Falls$11K
- Dallin GamblesRexburg$10K
- Cali BradberryBoise$9K
- Weldon RichardsonIdaho Falls$8K
- Michael WucinichTwin Falls$8K
- Wade ChristensenIdaho Falls$8K
- Joshua HansenIdaho Falls$8K
- Tyler HepworthPocatello$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.